AU2021333902A1 - Methods for the treatment of cholesterol crystal embolization with cyclodextrins - Google Patents

Methods for the treatment of cholesterol crystal embolization with cyclodextrins Download PDF

Info

Publication number
AU2021333902A1
AU2021333902A1 AU2021333902A AU2021333902A AU2021333902A1 AU 2021333902 A1 AU2021333902 A1 AU 2021333902A1 AU 2021333902 A AU2021333902 A AU 2021333902A AU 2021333902 A AU2021333902 A AU 2021333902A AU 2021333902 A1 AU2021333902 A1 AU 2021333902A1
Authority
AU
Australia
Prior art keywords
individual
cyclodextrin
beta
amount
cholesterol crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021333902A
Other languages
English (en)
Inventor
Jason CAMM
Diana KERWIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beren Therapeutics PBC
Original Assignee
Beren Therapeutics PBC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics PBC filed Critical Beren Therapeutics PBC
Publication of AU2021333902A1 publication Critical patent/AU2021333902A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AU2021333902A 2020-08-27 2021-08-27 Methods for the treatment of cholesterol crystal embolization with cyclodextrins Abandoned AU2021333902A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071222P 2020-08-27 2020-08-27
US63/071,222 2020-08-27
PCT/US2021/048072 WO2022047241A1 (en) 2020-08-27 2021-08-27 Methods for the treatment of cholesterol crystal embolization with cyclodextrins

Publications (1)

Publication Number Publication Date
AU2021333902A1 true AU2021333902A1 (en) 2023-03-16

Family

ID=80353289

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021333902A Abandoned AU2021333902A1 (en) 2020-08-27 2021-08-27 Methods for the treatment of cholesterol crystal embolization with cyclodextrins

Country Status (11)

Country Link
US (1) US20230330133A1 (https=)
EP (1) EP4203972A4 (https=)
JP (1) JP7835735B2 (https=)
KR (1) KR20230096975A (https=)
CN (1) CN116322643A (https=)
AU (1) AU2021333902A1 (https=)
BR (1) BR112023003455A2 (https=)
CA (1) CA3190563A1 (https=)
IL (1) IL300806A (https=)
MX (1) MX2023002419A (https=)
WO (1) WO2022047241A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
JP2024509376A (ja) * 2021-02-18 2024-03-01 ベレン セラピューティクス ピー．ビー．シー． 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.

Also Published As

Publication number Publication date
CN116322643A (zh) 2023-06-23
US20230330133A1 (en) 2023-10-19
JP7835735B2 (ja) 2026-03-25
BR112023003455A2 (pt) 2023-05-02
EP4203972A1 (en) 2023-07-05
MX2023002419A (es) 2023-07-11
KR20230096975A (ko) 2023-06-30
IL300806A (en) 2023-04-01
CA3190563A1 (en) 2022-03-03
WO2022047241A1 (en) 2022-03-03
JP2023543133A (ja) 2023-10-13
EP4203972A4 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
AU2022204217B2 (en) Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
US20230330133A1 (en) Methods for the treatment of cholesterol crystal embolization with cyclodextrins
CN108366963A (zh) 包含丹曲林的水性组合物
US20230375576A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
US20230302042A1 (en) Methods for the prevention of cholesterol crystal embolization with cyclodextrins
US20230091966A1 (en) Methods for the treatment of cardiovascular disease with cyclodextrins
US20240398849A1 (en) Methods for the treatment of hypertriglyceridemia with cyclodextrins
HK40084620A (en) Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
HK40009788A (en) Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period